Bone News and Research

RSS

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Substances naturally produced by the human body may one day help prevent paralysis following a spinal cord injury, according to researchers at Weill Cornell Medical College. A recent $2.5 million grant from the New York State Spinal Cord Injury Research Board will fund their research investigating this possibility.

6 Nov 2009

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.

6 Nov 2009

LDR reaches critical 24-month milestone in its Mobi-C cervical artificial disc study

LDR, a privately held company with innovative spinal implants for both non-fusion and fusion applications, reached the critical 24-month follow-up phase for the one-level IDE study on its second generation Mobi-C® cervical artificial disc. LDR is the first and currently the only company to have completed enrollment for a concurrent one-level and two-level cervical artificial disc replacement study. LDR completed 1-Level enrollment in October 2007 and 2-Level enrollment in March 2008.

6 Nov 2009

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Prevalence of lactose intolerance may be far lower than previously estimated, according to a study in the latest issue of Nutrition Today. The study, which uses data from a national sample of three ethnic groups, reveals that the overall prevalence rate of self-reported lactose intolerance is 12 percent - with 7.72 percent of European Americans, 10.05 percent of Hispanic Americans and 19.5 percent of African Americans who consider themselves lactose intolerant.

6 Nov 2009

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

In diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how these cells can escape from the bloodstream. This is no trivial feat, given that specialized blood vessels act as a barrier between the nervous system and the bloodstream.

6 Nov 2009

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

5 Nov 2009

SpineSmith Partners signs product development agreement with GenOsteo

SpineSmith Partners has signed an initial agreement with GenOsteo, Inc. to co-develop a unique scaffold that mimics the structure of natural cancellous bone.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

MiddleBrook Pharmaceuticals, Inc. today announced its financial and operational results for the quarter ended Sept. 30, 2009.

5 Nov 2009

Imagenetix awarded U.S. patent for its 1-TDC drug candidate to treat periodontal disease

Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.

5 Nov 2009

New Merck set to begin global health care operations

Merck & Co., Inc. today outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation announced yesterday. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.

5 Nov 2009

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.

4 Nov 2009

Shire receives FDA Priority Review for velaglucerase alfa NDA

Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.

4 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

Leprosy: Man's persistent companion

For thousands of years an undesirable and persistent companion has been travelling with man wherever he goes. Mycobacterium leprae, the bacterium that causes leprosy, has only one known natural host - mankind.

4 Nov 2009

Medical imaging cuts will cost lives

Medical imaging cuts contained in the 2010 Medicare Physician Fee Schedule will restrict life-saving imaging care to large hospitals, produce longer commutes and wait times to receive care, and cause life threatening delays in diagnosis and treatment of cancer and other serious illnesses.

4 Nov 2009

Bone News and Research

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

LDR reaches critical 24-month milestone in its Mobi-C cervical artificial disc study

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

SpineSmith Partners signs product development agreement with GenOsteo

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

Imagenetix awarded U.S. patent for its 1-TDC drug candidate to treat periodontal disease

New Merck set to begin global health care operations

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Shire receives FDA Priority Review for velaglucerase alfa NDA

Safeguard Scientifics reports financial results for the third quarter of 2009

Leprosy: Man's persistent companion

Medical imaging cuts will cost lives

Shorter toes in modern humans could be an evolutionary adaptation for efficient distance running

Lap band surgery effective for morbidly obese adolescents, improves glucose metabolism

Findings may lead to new drug therapies to reduce breast cancer metastasis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News